CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear The Centers for Medicare & Medicaid Services (CMS) this morning invited state Medicaid directors to pilot test giving up open-ended federal Medicaid funding for able-bodied adults in exchange for a …
Category: Regulatory
Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law” Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary to …
BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts …
Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending Companion bills filed this month in the Vermont House and Senate would require hospitals to report how much money they save through the 340B program and how …
(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share …
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility The Health Resources and Services Administration’s (HRSA) oversight of 340B private, nonprofit hospitals should be significantly strengthened, the Government Accountability Office (GAO) found in a report released this …
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts on …
Greetings Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news. BREAKING: Drugmaker Xspire Owes 340B Refunds Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for …